

Original article:**CARDIAC & PULMONARY COMPLICATIONS SEEN IN LIVER CIRRHOSIS-AN OBSERVATIONAL STUDY AT A TERTIARY CARE HOSPITAL**

Dr. Jyoti H. Vora^[a], Dr. Tehsim Memon^[a], DR. Karan Keshawala^[b]

- a) Department of General Medicine, Smt NHL Municipal Medical College, Gujarat University, Ahmedabad, Gujarat
- b) Department of General Medicine, BJ Medical College, Gujarat University, Ahmedabad, Gujarat.

Corresponding author: *Dr. Tehsim Memon*, department of General Medicine, Smt NHL Municipal Medical College, Gujarat University, Ahmedabad, Gujarat

ABSTRACT:

INTRODUCTION: Cirrhosis is a condition that is defined histopathologically and has a variety of clinical manifestations and complications, some of which can be life-threatening. Patients with cirrhosis and portal hypertension exhibit characteristic cardiovascular & pulmonary hemodynamic changes. The cardiovascular complications include systolic dysfunction, diastolic dysfunction & electrochemical abnormalities like prolonged QT interval in Electrocardiogram (ECG), and Respiratory complications include Consolidation, Pleural Effusion & Pulmonary Arterial Hypertension, which may be due to Hepatopulmonary or Portopulmonary syndrome

STUDY DESIGN: A two-year prospective observational study was conducted from July,2014 to June 2016

AIM: To study the different cardiac and pulmonary complications in the patients of Liver Cirrhosis.

MATERIALS & METHODS: A two-year prospective observational study was conducted from July,2014 to June 2016 at a tertiary care hospital in Ahmedabad, Gujarat, India, including 30 patients (>12 years old), who were known cases of cirrhosis of liver as well as those newly diagnosed with it, with cardiopulmonary complications, developed after liver cirrhosis, in the absence of other etiological factors. Clinical profile with laboratory studies and diagnostic tests were studied.

RESULTS: This study showed that cardiopulmonary complications in cirrhotic patients are more frequently seen in males than females, which commonly manifest during third & fourth decade. Dyspnoea is the most common symptom seen in the study. Among the pulmonary complications, Pneumonia & Hydrothorax are more common compared to hepatopulmonary & portopulmonary syndromes, and among cardiac complications, Diastolic dysfunction is a major complication in such patients, which increases with increasing severity of cirrhosis, as indicated by CP score.

CARDIOVASCULAR MANIFESTATIONS:

The hyperdynamic circulation, as described above, increases cardiac output, heart rate & blood volume, which eventually increases heart's work & oxygen demand ^[6,7]. In patients without cirrhosis, this would cause cardiac failure, but because of the decreased afterload as reflected by decreased systemic vascular resistance & increased arterial compliance, a left ventricular failure may be latent in cirrhosis. ^[7,8] Such Heart failure may manifest during physical stress (exercise), or pharmacological stress (treatment with vasoconstrictors) ^[9]. This type of cardiac dysfunction is known as **cirrhotic cardiomyopathy** and includes systolic dysfunction, diastolic dysfunction & electrochemical abnormalities like prolonged QT interval in Electrocardiogram (ECG).^[10] Various electrophysiological mechanisms for the conduction abnormalities and impaired cardiac contractility have been put forward, including reduced beta-adrenoreceptor density, post-receptor signal defects, abnormal excitation-contraction coupling, and metabolic abnormalities.⁽¹¹⁾

A) Systolic Dysfunction:

The Left Ventricular Ejection Fraction (LVEF) i.e. the stroke volume relative to the left ventricular end-diastolic volume, is an often-used measure of systolic function. At rest, LVEF has been normal in some studies ⁽¹²⁻¹⁴⁾ and reduced in one study in a subgroup of patients with ascites. ⁽¹⁵⁾ The functional capacity of heart decreases in cirrhosis, as reflected by some studies, in which the maximum aerobic exercise capacity and maximum heart rate are lower in most of the patients with cirrhosis^(9,13,16). Also, After exercise, the increase in LVEF is significantly less in cirrhotic patients than in controls.^(9,16,17) The reduced functional capacity may be attributed to a combination of factors such as blunted heart rate response to exercise, reduced myocardial reserve, & profound skeletal muscle wasting with impaired oxygen extraction.⁽¹³⁾

Also as described above, multiple studies have proved that physical or pharmacological stress usually unmasks the latent, underlying systolic dysfunction in cirrhotic patients^(9,16,18).

B) Diastolic Dysfunction:

In multiple studies, the cardiac hypertrophy, patchy fibrosis & subendothelial edema of cirrhotic patient's heart has been reported, all of which eventually lead to diastolic dysfunction. ^(11,17) In decompensated cirrhotic patients with ascites, diastolic dysfunction is aggravated after TIPS ^(19,20), and while Liver transplantation reverse all the cardiac abnormalities to normal, including diastolic dysfunction ⁽¹⁷⁾, paracentesis seems to reverse only diastolic dysfunction and not systolic dysfunction ⁽¹⁵⁾. Many studies have reported of unexpected death from heart failure following surgical procedures like portocaval shunts & TIPS ⁽²¹⁾. These procedures involve a rapid increase in cardiac preload in a less compliant

heart, during which the diastolic dysfunction is enough to cause pulmonary edema and heart failure. This is consistent with the findings of Hounker et al⁽²⁰⁾, who reported an increase in pulmonary artery pressure, pre-load, and diastolic dysfunction after TIPS. Diastolic dysfunction could thus account for part of the cardiac dysfunction in cirrhotic cardiomyopathy. This is further proven by multiple studies that have reported much increased A-wave (reflecting the late atrial contraction) & E-wave velocities (reflecting the early rapid trans mitral flow) and isovolumetric relaxation & deceleration times with decreased E/A ratio in Doppler-echocardiogram during diastole, in cirrhotic patients with ascites, which indicates diastolic dysfunction^(15,19).

C) Autonomic Dysfunction:

Most studies have found a high prevalence of autonomic dysfunction in cirrhosis with associations to liver dysfunction & survival^(22,23). The results of Mohamed et al⁽²⁴⁾ suggest that the autonomic dysfunction is temporary, arises as a result of liver dysfunction, and may be reversible after liver transplantation. Whereas most of the studies have focused on the sympathetic system dysfunction, recent papers have emphasized the importance of defects in parasympathetic system & vagal nerve conduction leading to sodium & fluid retention^(23,25). Sympathetic responses to dynamic exercise seem to be normal in patients with cirrhosis, but those to isometric exercise are clearly impaired^(26,27). Similarly, blood pressure responses to orthostasis are impaired, probably because of a blunted baroreflex function^(28,29).

PULMONARY MANIFESTATIONS:

Patients with cirrhosis often have complaint of breathlessness and decreased arterial oxygenation, which typically occurs while sitting up [platypnea]^(30,31). The etiology of abnormal lung function and ventilation in cirrhosis may be multifactorial and is often a combination of cardiac dysfunction, heavy smoking and Chronic obstructive pulmonary Disease (COPD), which is common in the patients with alcoholic cirrhosis⁽³²⁾. But independent of smoking status, patients with cirrhosis have a compromised lung function with a reduced transfer factor and ventilation/perfusion abnormalities⁽³²⁻³⁵⁾, and arterial hypoxemia is seen in 30-70% of the patients with chronic liver disease, depending on the severity⁽³⁶⁾.

A) HEPATOPULMONARY SYNDROME:

HPS is defined as the triad of liver disease, pulmonary gas exchange abnormalities leading to arterial deoxygenation, and evidence of intrapulmonary dilatations, in the absence of detectable primary cardiopulmonary disease⁽³⁵⁾. According to the hypothesis "peripheral arterial vasodilation", as described above, Primary vascular resistance of pulmonary circulation is also decreased in cirrhosis⁽³⁷⁾ which ultimately leads to increased perfusion as

compared to alveolar ventilation in many areas, leading to perfusion/ventilation mismatch⁽³³⁾. Besides the abnormal ventilation/perfusion ratio and the presence of regular pulmonary arteriovenous shunts, intrapulmonary vascular dilatations have also been described^(34,37). Pulmonary angiography of these patients has revealed two types of patterns with a spongiform appearance of the vessels & small arteriovenous communications⁽³⁴⁾. Fallon et al⁽³⁸⁾ have recently reported increased pulmonary vascular endothelial NOS to be the major cause. The diagnosis of the hepatopulmonary syndrome is based on arterial hypoxemia ($\text{PaO}_2 < 9.31 \text{ kPa}$), an age-adjusted increased alveolar-arterial oxygen gradient ($> 2.66 \text{ kPa}$) and intrapulmonary vasodilatation⁽³⁹⁾. A 100% oxygen shunt study with the patient breathing 100% oxygen may discriminate between functional & anatomic shunts⁽³⁴⁾. Contrast enhanced echocardiography is considered as the method of choice in the diagnosis of the HPS⁽⁴⁰⁾.

B) PORTOPULMONARY SYNDROME:

Portopulmonary hypertension is defined as pulmonary arterial hypertension (PAH) associated with portal hypertension, in the absence or presence of underlying liver disease⁽⁴¹⁻⁴³⁾ and is diagnosed as a mean pulmonary artery pressure $> 3.325 \text{ kPa}$ and pulmonary vascular resistance $> 120 \text{ dyn.s/cm}^5$, and normal left atrial pressure ($< 1.995 \text{ kPa}$)⁽³⁷⁾. It is rare in cirrhosis with an average prevalence from 1% to 4%⁽⁴⁴⁾. Symptoms are typically progressive and include fatigue, dyspnea & edema⁽³⁴⁾. The histologic appearance of pulmonary vessels is similar to that seen in primary pulmonary hypertension and includes smooth muscle proliferation & hypertrophy⁽³⁹⁾. Local vasoconstrictor systems, like the endothelin system, may play a role and recently the administration of a mixed ET-antagonist has showed beneficial effects in portopulmonary hypertension^(45,46).


MATERIAL AND METHODS:

A two-year prospective observational study was conducted from July, 2014 to June 2016 at a tertiary care hospital in Ahmedabad, Gujarat, India. The study included 30 patients (> 12 years old), who were known cases of cirrhosis of liver as well as those newly diagnosed with it (fibronodular chronic changes with altered echotexture & irregular margins with decreased size in ultrasonography), with cardiopulmonary complications, developed after liver cirrhosis, in the absence of other etiological factors. Their detailed history was taken, and complete general, physical and systemic examination was done. The following haematological investigations were carried out for all the patients – Arterial Blood Gas Analysis (ABGA), Haemoglobin (Hb), Total Leucocyte Count (TLC), Platelet Count, Erythrocyte Sedimentation Rate (ESR), total & direct bilirubin, total proteins, serum albumin, prothrombin time (PT) & INR, serum urea & creatinine, serum sodium & potassium, Viral markers: HIV, HBsAg, HCV. Other investigations included: Ultrasonography (USG), Electrocardiogram (ECG), Echocardiography (2D ECHO), Chest Xray (PA), HRCT thorax, Coronary Angiography (CAG) & Pulmonary Function Test (PFT) were carried out according to availability & indications. Patients were categorised according to Child Pugh Score (CPS).

Patients <12 years old, with pre-existing cardiopulmonary diseases, active smokers & known case of Hypertension & Diabetes Mellitus were excluded from the study.

AGE IN YEARS	NUMBER OF CASES	PERCENTAGE (%)
13 TO 20	1	3.33
21-30	2	6.67
31-40	10	33.33
41-50	10	33.33
51-60	6	20
61-70	1	3.33
MEAN=43		
STANDARD DEVIATION=10.2		

TABLE 1: THE AGE DISTRIBUTION




Among 30 cases studies, maximum incidence was in 4th & 5th decade, of around 67%. The youngest patient was 18 years old, while the oldest was 65 years old.

SEX	NO. OF CASES	PERCENTAGE (%)
-----	--------------	----------------

MALE	22	73
FEMALE	8	27


TABLE 2: SEX DISTRIBUTION



The above table & pie chart show that in liver cirrhosis, cardiopulmonary complications are more common in the males than females.

SYMPTOMS	NO. OF PATIENTS	PERCENTAGE (%)
DYSPNOEA	29	96.66
CHEST PAIN	6	20
PALPITATION	2	6.67

TABLE 3: INCIDENCE OF THE PRESENTING SYMPTOMS.




In this study, most of the patients, i.e. 96.6% presented with complaint of dyspnea.

CAUSE	NO. OF CASES	PERCENTAGE (%)
ALCOHOLISM	21	70

HEPATITS B	3	10
NASH	3	10
HEPATITS C	2	6.67
CRYPTOGENIC	1	3.33


TABLE 4: CAUSES OF CIRRHOSIS IN THIS STUDY



In this study, most of the patients had cirrhosis due to chronic alcoholism (70%).

COMPLICATIONS	NO. OF PATIENTS	PERCENTAGE (%)
CARDIAC	15	50
PULMONARY	14	46.6
CARDIAC & PULMONARY BOTH	1	3.33

TABLE 5: INCIDENCE OF VARIOUS CARDIAC & PULMONARY COMPLICATIONS IN LIVER CIRRHOSIS PATIENTS.



In this study, 50 % of the patients had cardiac complication and around 46% had pulmonary complications, while only 1 patient had both cardiac as well as pulmonary complications.

COMPLICATIONS	NO. OF PATIENTS	PERCENTAGE (%)
CARDIAC		
DIASTOLIC DYSFUNCTION	9	30
LONG QT INTERVAL	8	26.66
CARDIOMEGALY	8	26.99
SYSTOLIC DYSFUNCTION	1	3.33
PULMONARY		
CONSOLIDATION	8	26.66
PLEURAL EFFUSION	7	23.33
PULMONARY HYPERTENSION*	7	23.33

*Includes moderate to severe pulmonary hypertension with RVSP>40 mmHg.

TABLE 6: INCIDENCE OF VARIOUS CARDIAC & PULMONARY COMPLICATIONS COMPARE TO TOTAL PATIENTS INCLUDED IN THE STUDY.

The table shows that among cardiac complications, diastolic dysfunction (30%) is more common than systolic dysfunction (3.33%), & among pulmonary complications, consolidation (26.66%) is more common than pulmonary hypertension (23.33%) & pleural effusion (23.33%).

RVSP (mmHg)	NO. OF PATIENTS	PERCENTAGE (%)
<25 (NO PH)	4	13.33
25-40 (MILD PH)	19	63.33
>40 (MODERATE-SEVERE PH)	7	23.33
MEAN=33.8		
STANDARD DEVIATION=6.7		

TABLE 7: RVSP (RIGHT VENSTRICULAR SYTOLIC PRESSURE) OF THE PATIENTS INCLUDED IN THE STUDY, ON 2D ECHO.

According to the analysis, most of the patients (63.33%) in our study had mild Pulmonary Hypertension (PH), while only 23% had moderate to severe PH, due to any cause including Hepato-pulmonary & Porto-pulmonary syndromes.

ARTERIAL PARTIAL PRESSURE OF OXYGEN=PaO ₂ (mmHg)	NO. OF PATIENTS	PERCENTAGE (%)
>80 [NORMAL]	3	10
60-79 [MILD]	23	76.6
40-59 [MODERATE]	4	13.33
<40 [SEVERE]	0	0

TABLE 8: HYPOXEMIA IN THE PATIENTS INCLUDED IN OUR STUDY.

In our study, most of the patients (76%) had mild hypoxemia, while only 13% had moderate hypoxemia & 10 % had no hypoxemia.


CHILD PUGH SCORE: CPS, initially termed as Child-Turcotte score, was proposed more than 30 years ago. It was originally designed for predicting the outcome after surgery for portal hypertension (portocaval shunting and transection of the esophagus) in patients with cirrhosis. Child-Turcotte score included two continuous variables: **Bilirubin & Albumin**, and three discrete variables: **Ascites, Encephalopathy & nutritional status**, which were empirically selected because they were felt to have their own influence on the prognosis in the context.

CPS CLASS	SEVERITY	ABDOMINAL SURGERY PERI-OPERATIVE MORTALITY	1 YEAR SURVIVAL	LIFE EXPECTANCY
A (5 to 6 points)	LEAST SEVERE	10%	100%	15-20 years
B (7 to 9 points)	MODERATELY SEVERE	30%	80%	candidate for liver transplant
C (10 to 15 points)	MOST SEVERE	82%	45%	1-3 months

TABLE 9: INTERPRETATION OF CPS.

CHILD PUGH SCORE (CPS)	NO. OF PATIENTS	PERCENTAGE (%)
A	5	17
B	8	27
C	17	56

TABLE 10: DISTRIBUTION OF OUR PATIENTS ACCORDING TO CPS.




DISCUSSION:

The two-year prospective observational study was conducted from July 2014 to June 2016 at a tertiary care hospital; total of 30 cirrhotic patients with cardio-pulmonary complications were studied.

	Present Study	Tsung-Hsing Hung et al. ⁴⁷
Incidence of Pneumonia	26%	21.40%

TABLE 11: INCIDENCE OF PNEUMONIA [CONSOLIDATION]



According to this study, 26% of the cirrhotic patients developed pneumonia in the form of consolidation, which included community, hospital-acquired & Aspiration Pneumonia. These findings are comparable with the Tsung-Hsing Hung⁴⁷, in which 21% of the patients had pneumonia. Cirrhotic patients are more prone to develop infectious diseases because of their underlying immunocompromised status. Also, Hepatic Encephalopathy & tracheal intubations are usually considered to be the risk factors for the development of Pneumonia in cirrhotic patients. In addition, plasma-based blood products transfusion increases the risk

acute lung injury & pneumonia. In order to prevent cirrhotic patients from developing pneumonia, it is critical to avoid needless transfusions & influenza infections ⁽⁴⁷⁾.

	Present Study	Amr M. Helmy et al.⁴⁸
Hepatic Hydrothorax	23%	23.34%

TABLE 12: INCIDENCE OF HEPATIC HYDROTHORAX.

Our study showed that around 23% developed hydrothorax, which is comparable to Amr M.Helmy study⁴⁸, which also shows that 23% developed hydrothorax.

Hepatic hydrothorax or Pleural Effusion due to Cirrhosis is typically right sided, which usually coexists with ascites, although it can also be present without significant ascites. The mechanism of hydrothorax is thought to be due to diaphragmatic defects, which allow the seepage of ascitic fluid from abdomen, through hepatic surface, into the pleural space. The negative intrathoracic pressure draws the fluid into the pleural space. Consequently, Pleural Fluid analysis shows similar characteristics to that of ascitic fluid.

STUDY	INCIDENCE OF PULMONARY HYPERTENSION
AMR M. HELMY ⁴⁸	12%
THEVENOT ET AL ⁴⁹	20%
KARI ET AL ⁵⁰	24%
PRESENT STUDY	23.33%

TABLE 13: INCIDENCE OF PULMONARY HYPERTENSION.

In our study, we have taken the RVSP as a marker of pulmonary hypertension, and patients with RVSP>40 mmHg, are included in this table. In our study, 23% of the patients developed Pulmonary Hypertension, which is comparable to the studies like Thevenot et al⁴⁹, in which 20% of the patients & Kari et al⁵⁰, in which 24% of the patients developed pulmonary hypertension.

This pulmonary hypertension in liver cirrhosis can be due to hepatopulmonary syndrome, portopulmonary syndrome, due to long standing respiratory infections, secondary to cardiac involvement or may be primary.

STUDY	INCIDENCE OF PROLONGED QT INTERVAL
--------------	---

S. PATIL ET AL ⁵¹	33.33%
KOSER ET AL ⁵²	32%
PRESENT STUDY	27%

TABLE 14: INCIDENCE OF PROLONGED QT INTERVAL.

In our study, ECG showed QT prolongation in 27% of the patients, while in other studies like S.Patil et al⁵¹ & Koser et al⁵², it was present in 33% & 32%, respectively.

This ECG finding was unrelated to the etiology of cirrhosis but was positively related to the severity of disease. It may reflect electrolyte abnormalities, especially those of calcium, hyperbilirubinemia, myocardial ischemia, drugs & alcohol toxicity, and hypersensitivity of autonomic nervous system.

SEX	PRESENT STUDY	S. PATIL ET AL ⁵¹
MALES	73%	68.33%
FEMALES	27%	32%

TABLE 15: PERCENTAGE OF MALE & FEMALE PATIENTS COMPLICATED BY CARDIOPULMONARY SYMPTOMS IN LIVER CIRRHOSIS.

This table concludes that, in our study, the cardiopulmonary complications in liver cirrhosis is more common in males (73%) than in females (27%), which is comparable to the study S. Patil et al⁽⁵¹⁾, mentioned in the table. In our country, males are more commonly alcoholic than females, which could be the reason for same⁽⁵¹⁾.

CHILD PUGH SCORE (CPS)	PRESENT STUDY	SALARI ET AL ⁵²
A	22.22%	18.20%
B	33.30%	47.40%
C	44.50%	55%

TABLE 16: RELATION OF CPS & DIASTOLIC DYSFUNCTION.

This table suggests the significant correlation between severity of cirrhosis, in the form of Child Pugh Score (CPS), and diastolic dysfunction in our study. As the severity increases from score A to C, normal diastolic function decreases. The same has been proved by Salari et al study⁽⁵²⁾. This diastolic dysfunction can be due to stiffened ventricular wall as a result of cardiac hypertrophy described in cirrhotic cardiomyopathy.

LIMITATIONS OF THE STUDY:

Ideally, hepatopulmonary and portopulmonary syndromes are diagnosed based on contrast echocardiography & other investigations, but we had no facility for such investigations, so

we have not included such patients separately in the study. Instead, we have studied them commonly as pulmonary hypertension based on RVSP.

CONCLUSION:

The study showed that cardiopulmonary complications in cirrhotic patients are more frequently seen in males than females, which commonly manifest during third & fourth decade. Dyspnoea is the most common symptom seen in the study. Alcohol is a major risk factor for liver cirrhosis as well as for high incidence of cardiopulmonary complications in cirrhotic patients, followed by viral hepatitis.

Cardiac and pulmonary complications have nearly the same incidences. Among the pulmonary complications, Pneumonia & Hydrothorax are more common compared to hepatopulmonary & portopulmonary syndromes. Diastolic dysfunction is a major cardiac complication in such patients, which increases with increasing severity of cirrhosis, as indicated by CP score. Electrophysiologic abnormalities are also seen in many patients compared to other cardiac complications, seen in the form of prolonged QT interval in ECG. Most cirrhotic patients have mild pulmonary hypertension with dyspnoea as a major symptom.

NOTE: NO CONFLICT OF INTEREST.

REFERENCES:

1. **Kasper D**, Fauci A, Hauser S et al. Harrison's principles of Internal Medicine, 20th edition, New York: McGraw Hill Education.
2. **James Doodley** Sherlock's disease of liver and biliary system 12th edition Wiley Blackwel 2012
3. **Groszmann RJ**. Vasodilatation and hyperdynamic circulatory state in chronic liver disease. *Portal hypertension. Pathophysiology and treatment. 1 ed.* Oxford: Blackwell 1994; 17-26.
4. **Schrier RW**, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. *Hepatology*. 1988;**8**:1151-1157. [[PubMed](#)]
5. **Arroyo V**, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. *J Hepatol*. 2003;**38** Suppl 1:S69-S89. [[PubMed](#)]
6. **Møller S**, Bendtsen F, Henriksen JH. Splanchnic and systemic hemodynamic derangement in decompensated cirrhosis. *Can J Gastroenterol*. 2001;**15**:94-106. [[PubMed](#)]
7. **Møller S**, Henriksen JH. Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. *Heart*. 2002;**87**:9-15. [[PubMed](#)]
8. **Liu H**, Song D, Lee SS. Cirrhotic cardiomyopathy. *Gastroenterol Clin Biol*. 2002;**26**:842-847. [[PubMed](#)]
9. **Kelbaek H**, Eriksen J, Brynjolf I, Raboel A, Lund JO, Munck O, Bonnevie O, Godtfredsen J. Cardiac performance in patients with asymptomatic alcoholic cirrhosis of the liver. *Am J Cardiol*. 1984;**54**:852-825.
10. **Ma Z**, Lee SS. Cirrhotic cardiomyopathy: getting to the heart of the matter. *Hepatology*. 1996;**24**:451-459. [[PubMed](#)]
11. **Møller S**, Henriksen JH. Cardiovascular dysfunction in cirrhosis. Pathophysiological evidence of a cirrhotic cardiomyopathy. *Scand J Gastroenterol*. 2001;**36**:785-794. [[PubMed](#)]
12. **Kelbaek H**, Rabøl A, Brynjolf I, Eriksen J, Bonnevie O, Godtfredsen J, Munck O, Lund JO. Haemodynamic response to exercise in patients with alcoholic liver cirrhosis. *Clin Physiol*. 1987;**7**:35-41. [[PubMed](#)]
13. **Grose RD**, Nolan J, Dillon JF, Errington M, Hannan WJ, Bouchier IA, Hayes PC. Exercise-induced left ventricular dysfunction in alcoholic and non-alcoholic cirrhosis. *J Hepatol*. 1995;**22**:326-332. [[PubMed](#)]
14. **Møller S**, Søndergaard L, Møgelvang J, Henriksen O, Henriksen JH. Decreased right heart blood volume determined by magnetic resonance imaging: evidence of central underfilling in cirrhosis. *Hepatology*. 1995;**22**:472-478. [[PubMed](#)]

15. **Pozzi M**, Carugo S, Boari G, Pecci V, de Ceglia S, Maggiolini S, Bolla GB, Roffi L, Failla M, Grassi G. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. *Hepatology*. 1997;**26**:1131-1137. [[PubMed](#)]
16. **Wong F**, Girgrah N, Graba J, Allidina Y, Liu P, Blendis L. The cardiac response to exercise in cirrhosis. *Gut*. 2001;**49**:268-275. [[PubMed](#)]
17. **Torregrosa M**, Aguadé S, Dos L, Segura R, González A, Evangelista A, Castell J, Margarit C, Esteban R, Guardia J. Cardiac alterations in cirrhosis: reversibility after liver transplantation. *J Hepatol*. 2005;**42**:68-74. [[PubMed](#)]
18. **Limas CJ**, Guiha NH, Lekagul O, Cohn JN. Impaired left ventricular function in alcoholic cirrhosis with ascites. Ineffectiveness of ouabain. *Circulation*. 1974;**49**:754-760. [[PubMed](#)]
19. **Finucci G**, Desideri A, Sacerdoti D, Bolognesi M, Merkel C, Angeli P, Gatta A. Left ventricular diastolic function in liver cirrhosis. *Scand J Gastroenterol*. 1996;**31**:279-284. [[PubMed](#)]
20. **Huonker M**, Schumacher YO, Ochs A, Sorichter S, Keul J, Rössle M. Cardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt. *Gut*. 1999;**44**:743-748. [[PubMed](#)]
21. **Lebrec D**, Giuily N, Hadengue A, Vilgrain V, Moreau R, Poynard T, Gadano A, Lassen C, Benhamou JP, Erlinger S. Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: a randomized trial. French Group of Clinicians and a Group of Biologists. *J Hepatol*. 1996;**25**:135-144. [[PubMed](#)]
22. **Rangari M**, Sinha S, Kapoor D, Mohan JC, Sarin SK. Prevalence of autonomic dysfunction in cirrhotic and noncirrhotic portal hypertension. *Am J Gastroenterol*. 2002;**97**:707-713. [[PubMed](#)]
23. **Dillon JF**, Nolan J, Thomas H, Williams BC, Neilson JM, Bouchier IA, Hayes PC. The correction of autonomic dysfunction in cirrhosis by captopril. *J Hepatol*. 1997;**26**:331-335. [[PubMed](#)]
24. **Mohamed R**, Forsey PR, Davies MK, Neuberger JM. Effect of liver transplantation on QT interval prolongation and autonomic dysfunction in end-stage liver disease. *Hepatology*. 1996;**23**:1128-1134. [[PubMed](#)]
25. **Hendrickse MT**, Triger DR. Vagal dysfunction and impaired urinary sodium and water excretion in cirrhosis. *Am J Gastroenterol*. 1994;**89**:750-757. [[PubMed](#)]
26. **Bernardi M**, Rubboli A, Trevisani F, Cancellieri C, Ligabue A, Baraldini M, Gasbarrini G. Reduced cardiovascular responsiveness to exercise-induced sympathoadrenergic stimulation in patients with cirrhosis. *J Hepatol*. 1991;**12**:207-216. [[PubMed](#)]
27. **MacGilchrist AJ**, Sumner D, Reid JL. Impaired pressor reactivity in cirrhosis: evidence for a peripheral vascular defect. *Hepatology*. 1991;**13**:689-694. [[PubMed](#)]
28. **Arranz CT**, Balaszczuk AM, Costa MA, Eizayaga FX, Romay S, Mongelli C, Lemberg A. Systemic baroreflex alterations in prehepatic portal hypertensive conscious rats. *Arch Physiol Biochem*. 1995;**103**:422-426. [[PubMed](#)]
29. **La Villa G**, Barletta G, Romanelli RG, Laffi G, Del Bene R, Vizzutti F, Pantaleo P, Mazzocchi V, Gentilini P. Cardiovascular effects of canrenone in patients with preascitic cirrhosis. *Hepatology*. 2002;**35**:1441-1448. [[PubMed](#)]

30. **Agustí AG**, Roca J, Bosch J, Rodriguez-Roisin R. The lung in patients with cirrhosis. *J Hepatol*. 1990;**10**:251-257. [[PubMed](#)]
31. **Moreau R**, Lee SS, Soupison T, Roche-Sicot J, Sicot C. Abnormal tissue oxygenation in patients with cirrhosis and liver failure. *J Hepatol*. 1988;**7**:98-105. [[PubMed](#)]
32. **Agusti AG**, Roca J, Rodriguez-Roisin R. Mechanisms of gas exchange impairment in patients with liver cirrhosis. *Clin Chest Med*. 1996;**17**:49-66. [[PubMed](#)]
33. **Møller S**, Becker U, Schifter S, Abrahamsen J, Henriksen JH. Effect of oxygen inhalation on systemic, central, and splanchnic haemodynamics in cirrhosis. *J Hepatol*. 1996;**25**:316-328. [[PubMed](#)]
34. **Agusti AG**, Roca J, Rodriguez-Roisin R. Mechanisms of gas exchange impairment in patients with liver cirrhosis. *Clin Chest Med*. 1996;**17**:49-66. [[PubMed](#)]
35. **Krowka MJ**. Hepatopulmonary syndromes. *Gut*. 2000;**46**:1-4. [[PubMed](#)]
36. **Møller S**, Hillingsø J, Christensen E, Henriksen JH. Arterial hypoxaemia in cirrhosis: fact or fiction. *Gut*. 1998;**42**:868-874. [[PubMed](#)]
37. **Hervé P**, Lebrec D, Brenot F, Simonneau G, Humbert M, Sitbon O, Duroux P. Pulmonary vascular disorders in portal hypertension. *Eur Respir J*. 1998;**11**:1153-1166. [[PubMed](#)]
38. **Fallon MB**, Abrams GA, Luo B, Hou Z, Dai J, Ku DD. The role of endothelial nitric oxide synthase in the pathogenesis of a rat model of hepatopulmonary syndrome. *Gastroenterology*. 1997;**113**:606-614. [[PubMed](#)]
39. **Rodríguez-Roisin R**, Krowka MJ, Hervé P, Fallon MB. Pulmonary-Hepatic vascular Disorders (PHD). *Eur Respir J*. 2004;**24**:861-880. [[PubMed](#)]
40. **Abrams GA**, Jaffe CC, Hoffer PB, Binder HJ, Fallon MB. Diagnostic utility of contrast echocardiography and lung perfusion scan in patients with hepatopulmonary syndrome. *Gastroenterology*. 1995;**109**:1283-1288. [[PubMed](#)]
41. **Porres-Aguilar M**, Zuckerman Mj. Portopulmonary hypertension: state of the art. *Ann Hepatol* 2008; **7**: 321–330. [[PubMed](#)]
42. **Golbin JM**, Krowka Mj. Portopulmonary hypertension. *Clin Chest Med* 2007; **28**: 203–218. [[PubMed](#)]
43. **Savale L**, O'Callaghan DS, Magnier R, et al. Current management approaches to portopulmonary hypertension. *Int J Clin Pract Suppl* 2011; **169**: 11–18. [[PubMed](#)]
44. **Hadengue A**, Benhayoun MK, Lebrec D, Benhamou JP. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. *Gastroenterology*. 1991;**100**:520-528. [[PubMed](#)]
45. **Kuntzen C**, Gülberg V, Gerbes AL. Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: a safe and effective therapy. *Gastroenterology*. 2005;**128**:164-168. [[PubMed](#)]
46. **Hung TH**, Tsai CC, Tseng CW. Effect of renal impairment on mortality of patients with cirrhosis and spontaneous bacterial peritonitis. *Clin Gastroenterol Hepatol*. 2012;**10**:677-681.
47. **Amr M. helmy**, Mohamed F, Awadalla: Study of Pulmonary dysfunction in liver cirrhosis, Al-Azhar University, Damietta, Egypt.
48. **C.M. Thevenot Pastor**, J.P. Cervoni, C. Jacquellnet, Hepatopulmonary syndrome, *Gastroenterol. Clin. Biol.* 33 (6–7) (2009) 565–579.

49. **E.R. Kari**, S.M. Kawut, M.J. Krowka, Genetic risk factors for hepato-pulmonary syndrome in patients with advanced liver disease, *Gastroenterology* 139 (1) (2010) 130–135.
50. **S. Patil**, Bajrang Lal: A clinical study of Cardiovascular Dysfunction in patients of Cirrhosis of Liver.
51. **Kosar F**, Ates F, Sahin I, Karıncaoglu M, Yildirim B. QT interval analysis in patients with chronic liver disease: a prospective study. *Angiology* 2007;58:218–24.
52. **A.Salari**, A. Shafaghi: Diastolic dysfunction and severity of Cirrhosis in Cirrhotic patients, Department of Cardiology, Guilan University of Medical Sciences (GUMS), Rasht, Iran.